Condition: Systemic Sclerosis · Interstitial Lung Disease · Sponsor: National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland
The study includes adult patients with systemic sclerosis (SSc) with interstitial lung disease (ILD) to evaluate the efficacy and safety of nintedanib plus tocilizumab combination therapy compared to standard therapy (methotrexate, mycophenolate mofetil) for 56 weeks.
This description comes directly from the study's public registry record.
Maria Maślińska, PhD, MD · 226880632 · maria.maslinska@spartanska.pl
Always discuss trial participation with your own doctor first.
| Centrum Wsparcia Badań Klinicznych | Warsaw, Masovian Voivodeship, Poland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06297096